Key R&D programs moving biotech stocks

TheSteet's Adam Feuerstein takes at look today at some of the most actively traded biotech stocks today, highlighting a number of companies such as AVEO Pharmaceuticals ($AVEO), Targacept ($TRGT) and Vertex Pharmaceuticals ($VRTX). These developers are awaiting key clinical data that are expected to boost of sink some of the companies' stocks. If nothing else, it's a good primer for several important drug R&D programs in the biotech industry. Item

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.